Holen Sie sich die Stockscreener-App
8.81
0.45%
-0.04
Handel nachbörslich:
8.61
-0.20
-2.27%
Schlusskurs vom Vortag:
$8.85
Offen:
$8.81
24-Stunden-Volumen:
1.29M
Relative Volume:
1.11
Marktkapitalisierung:
$989.64M
Einnahmen:
$47.56M
Nettoeinkommen (Verlust:
$-156.83M
KGV:
-4.8142
EPS:
-1.83
Netto-Cashflow:
$-127.98M
1W Leistung:
-8.23%
1M Leistung:
-3.29%
6M Leistung:
-16.18%
1J Leistung:
-37.61%
1-Tages-Spanne:
$8.5194
$8.91
1-Wochen-Bereich:
$8.5194
$9.6999
52-Wochen-Spanne:
$6.38
$17.30
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Firmenname
Avadel Pharmaceuticals Plc
Sektor
Telefon
636-449-1830
Adresse
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Vergleichen Sie AVDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
8.81 | 989.64M | 47.56M | -156.83M | -127.98M | -1.83 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.35 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.64 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-05 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-05 | Bestätigt | Needham | Buy |
| 2024-03-05 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2022-11-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-28 | Fortgesetzt | Craig Hallum | Buy |
| 2022-05-26 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-03 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Eingeleitet | Stifel | Buy |
| 2020-02-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-30 | Eingeleitet | Craig Hallum | Buy |
| 2019-06-14 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-02-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
Alle ansehen
Avadel Pharmaceuticals Plc Aktie (AVDL) Neueste Nachrichten
Form DEFA14A AVADEL PHARMACEUTICALS - StreetInsider
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High? - Yahoo Finance
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock - Yahoo Finance
AVDL Stock Update: Avadel Pharmaceuticals plc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Purchased by California State Teachers Retirement System - Defense World
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way? - simplywall.st
Following a 34% decline over last year, recent gains may please Avadel Pharmaceuticals plc (NASDAQ:AVDL) institutional owners - Yahoo Finance
Avadel Pharmaceuticals PLC (AVDL) Stock Price Up 3.29% on Jun 9 - GuruFocus
Lifesci Capital Has Optimistic Outlook of AVDL Q2 Earnings - Defense World
FDA Grants Orphan Drug Designation to IH Drug Contender - Sleep Review
Bank of America Corp DE Decreases Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel gets FDA's Orphan Drug status for sleep disorder treatment - MSN
FDA grants orphan drug status to Avadel’s IH treatment By Investing.com - Investing.com South Africa
Avadel Pharmaceuticals (AVDL) Secures FDA Orphan Drug Status - GuruFocus
Avadel Pharmaceuticals at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Avadel Pharmaceuticals (AVDL) Secures FDA Orphan Drug Status for LUMRYZ | AVDL Stock News - GuruFocus
Avadel Pharmaceuticals Receives FDA Orphan Drug Designation - TipRanks
Avadel Pharmaceuticals Receives Orphan Drug Designation From FDA For Lumryz - MarketScreener
FDA grants orphan drug status to Avadel’s IH treatment - Investing.com Australia
FDA Orphan Drug Designation Gives LUMRYZ 7-Year Market Exclusivity for Sleep Disorder Breakthrough - Stock Titan
AVDL Stock Quote Price and Forecast - CNN
Nuveen Asset Management LLC Purchases 54,773 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025 - MSN
ProShare Advisors LLC Has $322,000 Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 - The Manila Times
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet - Yahoo Finance
Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - TradingView
BNP Paribas Financial Markets Buys Shares of 23,292 Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $553,000 Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Ameriprise Financial Inc. Lowers Stock Holdings in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Cetera Investment Advisers Sells 24,747 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel wins appeal to expand LUMRYZ trials beyond narcolepsy By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals: One Step Forward, One Back (NASDAQ:JAZZ) - Seeking Alpha
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Bought by Northern Trust Corp - Defense World
Chesterfield pharmaceutical company adds C-suite role - The Business Journals
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy - Yahoo Finance
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year' (NASDAQ:AVDL) - Seeking Alpha
Price T Rowe Associates Inc. MD Acquires 6,445 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Avadel Pharmaceuticals appoints Susan Rodriguez as COO - MSN
AVDL Boosts Leadership with New COO Appointment | AVDL Stock News - GuruFocus
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer - The Manila Times
Avadel appoints new COO to boost narcolepsy drug growth By Investing.com - Investing.com Canada
Avadel Pharmaceuticals Appoints New Chief Operating Officer - TipRanks
Avadel appoints new COO to boost narcolepsy drug growth - Investing.com
Avadel Pharmaceuticals Expands Leadership Team With Appointment Of Susan Rodriguez As Chief Operating Officer - marketscreener.com
Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - The Manila Times
Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy? - Yahoo Finance
Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade - Yahoo Finance
Leerink Partnrs Issues Positive Estimate for AVDL Earnings - Defense World
Finanzdaten der Avadel Pharmaceuticals Plc-Aktie (AVDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avadel Pharmaceuticals Plc-Aktie (AVDL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thornton Peter J. | Director |
Jan 13 '25 |
Buy |
8.04 |
10,000 |
80,450 |
104,055 |
| Ende Eric J | Director |
Jan 13 '25 |
Buy |
7.84 |
30,000 |
235,218 |
208,900 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 13 '24 |
Buy |
10.44 |
2,300 |
24,019 |
87,800 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 11 '24 |
Buy |
10.49 |
5,000 |
52,432 |
85,500 |
| Divis Gregory J | Chief Executive Officer |
Dec 06 '24 |
Buy |
9.98 |
9,598 |
95,759 |
9,598 |
| Divis Gregory J | Chief Executive Officer |
Dec 09 '24 |
Buy |
9.82 |
402 |
3,948 |
10,000 |
| Glass Geoffrey Michael | Director |
Dec 10 '24 |
Buy |
9.84 |
20,279 |
199,641 |
75,904 |
| Palczuk Linda | Director |
Dec 06 '24 |
Buy |
10.19 |
3,000 |
30,568 |
66,400 |
1.05%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):